Table 3.

Frequency of AEs (N = 64)

	Any grade	Grade 3	Grade 4
TRAEs
Any TRAEs	61 (95.3)	14 (21.9)	3 (4.7)
Proteinuria	30 (46.9)	0 (0.0)	0 (0.0)
Hypertension	23 (35.9)	2 (3.1)	0 (0.0)
Hypothyroidism	20 (31.3)	0 (0.0)	0 (0.0)
Aspartate aminotransferase increased	17 (26.6)	0 (0.0)	0 (0.0)
Platelet count decreased	15 (23.4)	4 (6.3)	0 (0.0)
Weight decreased	15 (23.4)	0 (0.0)	0 (0.0)
Palmar-plantar erythrodysaesthesia syndrome	13 (20.3)	4 (6.3)	0 (0.0)
Lipase increased	12 (18.8)	2 (3.1)	1 (1.6)
Amylase increased	10 (15.6)	1 (1.6)	0 (0.0)
Blood creatine phosphokinase MB increased	10 (15.6)	0 (0.0)	0 (0.0)
Blood lactate dehydrogenase increased	10 (15.6)	0 (0.0)	0 (0.0)
Blood bilirubin increased	9 (14.1)	0 (0.0)	0 (0.0)
Rash	8 (12.5)	0 (0.0)	0 (0.0)
White blood cell count decreased	7 (10.9)	1 (1.6)	0 (0.0)
Haematuria	7 (10.9)	0 (0.0)	0 (0.0)
Diarrhoea	7 (10.9)	0 (0.0)	0 (0.0)
Dysphonia	7 (10.9)	0 (0.0)	0 (0.0)
imAEs
Any imAEs	30 (46.9)	3 (4.7)	0 (0.0)
Hypothyroidism	20 (31.3)	0 (0.0)	0 (0.0)
Rash	8 (12.5)	0 (0.0)	0 (0.0)
Hyperthyroidism	3 (4.7)	0 (0.0)	0 (0.0)
Myositis	2 (3.1)	0 (0.0)	0 (0.0)
Pancreatitis	2 (3.1)	2 (3.1)	0 (0.0)
Thyroiditis	2 (3.1)	0 (0.0)	0 (0.0)
Adrenal insufficiency	1 (1.6)	0 (0.0)	0 (0.0)
Enterocolitis	1 (1.6)	1 (1.6)	0 (0.0)

Data are presented as n (%). TRAEs at any grade occurring in ≥ 10% of patients are listed. No grade 5 adverse events occurred among TRAEs reported at an overall frequency of ≥ 10%. imAEs occurring in ≥ 1 patient. Data are listed in order of decreased frequency of any grade TRAE. AEs Adverse events, TRAEs Treatment-related adverse events, imAEs Immune-mediated adverse events